[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100407991":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":31,"locations":41,"responsibleParty":59,"collaborators":62,"id":65,"slug":20,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":20,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":20,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":88,"overallStatus":43,"whyStopped":20,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"hAMSC Treatment Group","EXPERIMENTAL","hAMSC treatment regimen: (1) Intravenous infusion: 1.0×10⁶ cells\u002Fkg administered three times consecutively at weeks 1, 2, and 4, followed by once every 4 weeks for a total of 8 doses (6 months). (2) Local injection: 2.0×10⁴ cells\u002Fcm² of wound area, administered concurrently. Treatment may be terminated earlier or extended based on clinical condition.",[13],"Biological: Human amniotic-derived mesenchymal stem cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Human amniotic-derived mesenchymal stem cells","(1) Intravenous infusion: 1.0×10⁶ cells\u002Fkg administered three times consecutively at weeks 1, 2, and 4, followed by once every 4 weeks for a total of 8 doses (6 months). (2) Local injection: 2.0×10⁴ cells\u002Fcm² of wound area, administered concurrently. Treatment may be terminated earlier or extended based on clinical condition.",[9],null,[22,26,29],{"name":23,"affiliation":24,"role":25},"Ningning Wang, Professor","The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":28},"Jiayin Liu, Professor","STUDY_DIRECTOR",{"name":30,"affiliation":24,"role":25},"Lianju Qin",[32,37],{"name":23,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","86-013813821064","+8613813821064","wangnn@njmu.edu.cn",{"name":38,"role":33,"phone":39,"phoneExt":20,"email":40},"Lianju Qin, Professor","86-018012923584","ljqin@njmu.edu.cn",[42],{"facility":24,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Nanjing","Jiangsu","210029","China","CN",{"type":50,"coordinates":51},"Point",[52,53],118.77778,32.06167,{"lat":53,"lon":52},[56,58],{"name":23,"role":33,"phone":57,"phoneExt":20,"email":36},"+86-013813821064",{"name":38,"role":33,"phone":39,"phoneExt":20,"email":40},{"type":25,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Ningning Wang","Professor",[63],{"name":64,"class":6},"Westlake University","100407991",false,"NCT04592640","Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis","Effects of Human Amniotic-derived Mesenchymal Stem Cells (hAMSCs) on Calciphylaxis Patients: An Open-Label Single-Arm Study","Inclusion Criteria:\n\n1. 18-75 years old.\n2. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).\n3. All subjects signed informed consent.\n\nExclusion criteria:\n\n1. Patients who refuse to sign informed consent.\n2. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.\n3. Pregnant or lactating women of childbearing age.\n4. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.","ALL","18 Years","75 Years",{"count":75,"type":76},9,"ESTIMATED","INTERVENTIONAL",[79],"EARLY_PHASE1","Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells",[82,83,84,85,86,87],"Chronic Kidney Diseases","Calciphylaxis","Calcific Uremic Arteriolopathy","Treatment","Safety","Efficacy",[82,83,84,89,90,86,87],"Human Amniotic-derived Mesenchymal Stem Cells","Rare disease (ORPHA280062)","2026-03-02",{"date":93,"type":94},"2026-03-04","ACTUAL",{"date":96,"type":94},"2018-09-17",{"date":98,"type":76},"2028-09-17",{"name":5,"class":6},1]